Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335(12), 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am.20(2), 303–321 (1993).
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13(3), 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.14(8), 2410–2411 (1996).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol.154(1), 32–34 (1995).
   PubMed Web of Science ®Google Scholar
• Spencer WF, Linehan WM, Walther MM et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J. Urol.147(1), 24–30 (1992).
   PubMed Web of Science ®Google Scholar
• Tanguay S, Swanson DA, Putnam JB Jr. Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J. Urol.156(5), 1586–1589 (1996).
   PubMed Web of Science ®Google Scholar
• Tykka H. Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study. Scand. J. Urol. Nephrol. Suppl.63, 1–107 (1981).
   Google Scholar
• Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol.158(5), 1675–1678 (1997).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171(3), 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol.178(5), 1896–1900 (2007).
   PubMed Web of Science ®Google Scholar
• Joffe JK, Banks RE, Forbes MA et al. A Phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br. J. Urol.77(5), 638–649 (1996).
   PubMedGoogle Scholar
• Van Poppel H, Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol. Belg.64(2), 11–17 (1996).
   PubMedGoogle Scholar
• Walther MM, Alexander RB, Weiss GH et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology42(3), 250–257; discussion 257–258 (1993).
   PubMed Web of Science ®Google Scholar
• Walther MM, Lyne JC, Libutti SK, Linehan WM. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology53(3), 496–501 (1999).
   PubMed Web of Science ®Google Scholar
• Hutterer GC, Patard JJ, Colombel M et al. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer (2007) (Epub ahead of print).
   Google Scholar
• Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J. Urol.176(5), 1990–1995; discussion 1995 (2006).
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. Interleukin-2 toxicity. J. Clin. Oncol.9(4), 694–704 (1991).
   PubMed Web of Science ®Google Scholar
• Negrier S, Gomez F, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. World J. Urol.23(3), 161–165 (2005).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med.345(23), 1711–1712 (2001).
   PubMed Web of Science ®Google Scholar
• Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur. Urol.48(1), 77–81; discussion 81–82 (2005).
   PubMed Web of Science ®Google Scholar
• Brugarolas J. Renal-cell carcinoma – molecular pathways and therapies. N. Engl. J. Med.356(2), 185–187 (2007).
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH III, Treiber DK et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol.23(3), 329–336 (2005).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol.25(29), 4536–4541 (2007).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J. Clin. Oncol.25(18S), (2007) (Abstract 3).
   PubMedGoogle Scholar
• Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res.10(8), 2584–2586 (2004).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol.25(18S), (2007) (Abstract 5023).
   Google Scholar
• Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol.25(18S), (2007) (Abstract 5025).
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295(21), 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin.57(2), 112–125 (2007).
   PubMed Web of Science ®Google Scholar
• Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A Phase II study of RAD001 in metastatic renal cell cancer J. Clin. Oncol.25(18S), (2007) (Abstract 5107)
   Google Scholar
• Porter LL, Burris HA, Jones SF et al. Summary of results in patients with metastatic renal cell (RCC) from phase I studies of RAD001 (everolimus). J. Clin. Oncol.24(18S), (2006) (Abstract 14599).
   Google Scholar
• Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer107(10), 2375–2383 (2006).
   PubMed Web of Science ®Google Scholar
• Haas GP, Redman BG, Rao VK, Dybal E, Pontes JE, Hillman GG. Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J. Immunother. Emphasis Tumor Immunol.13(2), 130–135 (1993).
   Google Scholar
• Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol.152(5 Pt 1), 1399–1403 (1994).
   PubMed Web of Science ®Google Scholar
• Sella A, Swanson DA, Ro JY et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J. Urol.149(1), 19–21; discussion 21–22 (1993).
   PubMed Web of Science ®Google Scholar
• Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur. Urol.42(6), 570–574; discussion 575–576 (2002).
   PubMed Web of Science ®Google Scholar
• Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur. Urol.49(1), 76–81 (2006).
   PubMed Web of Science ®Google Scholar
• Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res.13(2 Pt 2), S697–S702 (2007).
   Google Scholar
• Verra N, Jansen R, Groenewegen G et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br. J. Cancer88(9), 1346–1351 (2003).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa 2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med.338(18), 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J. Urol.171(5), 1806–1809 (2004).
   PubMed Web of Science ®Google Scholar
• Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med.34(4), 274–292 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin. Cancer Res.13(2 Pt 2), S770–S776 (2007).
   Google Scholar